BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38104924)

  • 1. Mitochondrial ribosomal protein L12 potentiates hepatocellular carcinoma by regulating mitochondrial biogenesis and metabolic reprogramming.
    Ji X; Yang Z; Li C; Zhu S; Zhang Y; Xue F; Sun S; Fu T; Ding C; Liu Y; Wan Q
    Metabolism; 2024 Mar; 152():155761. PubMed ID: 38104924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
    Pu Z; Duda DG; Zhu Y; Pei S; Wang X; Huang Y; Yi P; Huang Z; Peng F; Hu X; Fan X
    J Transl Med; 2022 May; 20(1):212. PubMed ID: 35562734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
    Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
    Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of lncRNA FER1L4 suppresses the proliferation and migration of the hepatocellular carcinoma via regulating PI3K/AKT signal pathway.
    Wang X; Dong K; Jin Q; Ma Y; Yin S; Wang S
    J Cell Biochem; 2019 Apr; 120(4):6781-6788. PubMed ID: 30382631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway.
    Zhou C; Liu C; Liu W; Chen W; Yin Y; Li CW; Hsu JL; Sun J; Zhou Q; Li H; Hu B; Fu P; Atyah M; Ma Q; Xu Y; Dong Q; Hung MC; Ren N
    Theranostics; 2020; 10(10):4627-4643. PubMed ID: 32292519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.
    Yang YF; Zhang MF; Tian QH; Fu J; Yang X; Zhang CZ; Yang H
    Mol Cancer; 2018 Aug; 17(1):117. PubMed ID: 30089483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.
    Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N
    Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway.
    Wang J; Sun J; Zhang N; Yang R; Li H; Zhang Y; Chen K; Kong D
    Life Sci; 2019 Feb; 219():182-189. PubMed ID: 30630006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-34a and miR-125a-5p inhibit proliferation and metastasis but induce apoptosis in hepatocellular carcinoma cells via repressing the MACC1-mediated PI3K/AKT/mTOR pathway.
    Zhang YM; Wu QM; Chang LY; Liu JC
    Neoplasma; 2020 Sep; 67(5):1042-1053. PubMed ID: 32484698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
    Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
    Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways.
    Li Y; Xiong H
    BMC Cancer; 2022 Mar; 22(1):298. PubMed ID: 35313850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors.
    Li Y; Li B; Xu Y; Qian L; Xu T; Meng G; Li H; Wang Y; Zhang L; Jiang X; Liu Q; Xie Y; Cheng C; Sun B; Yu D
    Cancer Res; 2022 Sep; 82(18):3223-3235. PubMed ID: 35895805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA RHPN1-AS1 Promotes Cell Proliferation, Migration and Invasion Through Targeting miR-7-5p and Activating PI3K/AKT/mTOR Pathway in Hepatocellular Carcinoma.
    Song XZ; Ren XN; Xu XJ; Ruan XX; Wang YL; Yao TT
    Technol Cancer Res Treat; 2020; 19():1533033820957023. PubMed ID: 32910747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma.
    Zhao C; Wang B; Liu E; Zhang Z
    Cell Commun Signal; 2020 Aug; 18(1):131. PubMed ID: 32831114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
    Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
    Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DEPTOR induces a partial epithelial-to-mesenchymal transition and metastasis via autocrine TGFβ1 signaling and is associated with poor prognosis in hepatocellular carcinoma.
    Chen J; Zhu H; Liu Q; Ning D; Zhang Z; Zhang L; Mo J; Du P; Liu X; Song S; Fan Y; Liang H; Liu J; Zhang B; Chen X
    J Exp Clin Cancer Res; 2019 Jun; 38(1):273. PubMed ID: 31228948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Puerarin 6″-O-xyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR.
    Li L; Liu JD; Gao GD; Zhang K; Song YW; Li HB
    Cancer Med; 2020 Sep; 9(17):6399-6410. PubMed ID: 32691991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
    Zhang Z; Zhu J; Huang Y; Li W; Cheng H
    Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
    Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.